|

CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) Clinical Trials

1 actively recruiting trial across 1 location

Also known as: ulacamten

Pipeline

Phase 2: 1

Top Sponsors

  • Cytokinetics1

Indications

  • Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)1
  • Heart Disease1

Fairhope, Alabama1 trial

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

Eastern Shore Research Institute, LLC

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.